Skip to contentE
Emergent BioSolutions Inc.
E
EBSEmergent BioSolutions Inc. Q1 2024 · 10-Q
Revenue$300.40M$300.40M+82.8% vs Q1 2023 Net Income$9.00M$9.00MN/M vs Q1 2023 EPS Diluted$0.17$0.17N/M vs Q1 2023 Gross Profit$147,800,000+2,916.3% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Emergent BioSolutions Inc. · CIK 1367644 · Engraved from SEC EDGAR
Operating Cash Flow-$62,600,000N/M Free Cash Flowderived-$73,400,000N/M Margins · derivedGross margin49.2%+46.2 pt vs Q1 2023
Operating margin13.2%+103.1 pt vs Q1 2023
Net margin3.0%+116.3 pt vs Q1 2023
ended Mar 31, 2024 · filed May 2, 2024 · 32 d after period end